



# SAFETY DATA SHEET

Revision date 15-Jun-2025

Version 3

Page 1 / 13

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Product Name** Buprenorphine Hydrochloride Injection (Hospira Inc.)  
**Product Code(s)** PZ03252  
**Trade Name:** Buprenorphine Hydrochloride Injection  
**Chemical Family:** Not determined

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Pharmaceutical product used as Analgesic

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

**E-mail address** pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

**Emergency Telephone** Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

Not classified as hazardous.

#### OSHA Classification

##### Hazards not otherwise classified (HNOC)

Not applicable

##### Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

### 2.2. Label elements

**Signal word** Not classified

**Hazard statements** Not classified in accordance with international standards for workplace safety.

### 2.3. Other hazards

**Other hazards** An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

# SAFETY DATA SHEET

Product Name Buprenorphine Hydrochloride Injection (Hospira Inc.)  
Revision date 15-Jun-2025

Page 2 / 13  
Version 3

## PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

## Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

## Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

#### Substances

Not applicable

### 3.2 Mixtures

#### Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7 (017-002-00-2) (017-002-01-X)	Press. Gas Skin Corr. 1A (H314) Acute Tox. 3 (H331)	Eye Irrit. 2 :: 10%≤C<25% Skin Corr. 1B :: C≥25% Skin Irrit. 2 :: 10%≤C<25% STOT SE 3 :: C≥10%	No data available	No data available
Buprenorphine Hydrochloride (CAS #: 53152-21-9)	0.0324		258-396-8	Acute Tox 4 (H302) STOT SE 3 (H336)	Not classified	No data available	No data available

#### NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
Dextrose (CAS #: 14431-43-7)	*		Not Listed	Not classified	Not classified	No data available	No data available

## Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

# SAFETY DATA SHEET

Product Name Buprenorphine Hydrochloride Injection (Hospira Inc.)  
Revision date 15-Jun-2025

Page 3 / 13  
Version 3

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022
Buprenorphine Hydrochloride 53152-21-9	1000	No data available	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59).

## Additional information

\* Proprietary

\*\* to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

Inhalation	Move victim to fresh air.
Eye contact	Rinse thoroughly with plenty of water, also under the eyelids. If symptoms persist, call a physician.
Skin contact	Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

### 4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
-------------------------------------	--

### 4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians	None.
--------------------	-------

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

Suitable Extinguishing Media	Dry chemical, CO <sub>2</sub> , alcohol-resistant foam or water spray.
------------------------------	--

### 5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical	Not applicable.
--	-----------------

Hazardous combustion products	Formation of toxic gases is possible during heating or fire.
-------------------------------	--

# SAFETY DATA SHEET

Product Name Buprenorphine Hydrochloride Injection (Hospira Inc.)  
Revision date 15-Jun-2025

Page 4 / 13  
Version 3

## Explosion data

**Sensitivity to mechanical impact** No information available.

**Sensitivity to static discharge** No information available.

## 5.3. Advice for firefighters

**Special protective equipment and precautions for fire-fighters** Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.  
Use personal protection equipment.

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

**Personal precautions** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**For emergency responders** Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### 6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

**Methods for cleaning up** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

### 6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## Section 7: HANDLING AND STORAGE

### 7.1. Precautions for safe handling

**Advice on safe handling** Restrict access to work area. Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

### 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store as directed by product packaging.

### 7.3. Specific end use(s)

**Specific use(s)** Pharmaceutical drug product.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

# SAFETY DATA SHEET

Product Name Buprenorphine Hydrochloride Injection (Hospira Inc.)  
Revision date 15-Jun-2025

Page 5 / 13  
Version 3

## 8.1. Control parameters

### Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

#### Buprenorphine Hydrochloride

Pfizer OEL TWA-8 Hr: 0.4 µg/m<sup>3</sup>, Skin

#### + Hydrochloric Acid

ACGIH OEL (Ceiling)

ACGIH TLV

Austria

2 ppm

Ceiling: 2 ppm

TWA-TMW: 5 ppm;

TWA-TMW: 8 mg/m<sup>3</sup>;

STEL-KZGW: 10 ppm (8 X 5 min);

STEL-KZGW: 15 mg/m<sup>3</sup> (8 X 5 min);

Bulgaria

TWA: 5 ppm;

TWA: 8.0 mg/m<sup>3</sup>;

STEL: 10 ppm;

STEL: 15.0 mg/m<sup>3</sup>;

Czech Republic

8 mg/m<sup>3</sup>

Ceiling: 15 mg/m<sup>3</sup>

Denmark

STEL: 5 ppm;

STEL: 8 mg/m<sup>3</sup>;

Estonia

TWA: 5 ppm;

TWA: 8 mg/m<sup>3</sup>;

STEL: 10 ppm;

STEL: 15 mg/m<sup>3</sup>;

European Union

TWA: 5 ppm;

TWA: 8 mg/m<sup>3</sup>;

STEL: 10 ppm;

STEL: 15 mg/m<sup>3</sup>;

Finland

STEL: 5 ppm;

STEL: 7.6 mg/m<sup>3</sup>;

Germany DFG

TWA-MAK: 2 ppm; I(2);

TWA-MAK: 3.0 mg/m<sup>3</sup>; I(2);

Peak: 4 ppm;

Peak: 6 mg/m<sup>3</sup>;

Germany TRGS

TWA-AGW; 2 ppm (exposure factor 2);

TWA-AGW; 3 mg/m<sup>3</sup> (exposure factor 2);

Hungary

TWA-AK: 8 mg/m<sup>3</sup>;

TWA-AK: 5 ppm;

STEL-CK: 165 mg/m<sup>3</sup>;

STEL-CK: 10 ppm;

Ireland

TWA: 8 mg/m<sup>3</sup>;

TWA: 5 ppm;

STEL: 10 ppm;

STEL: 15 mg/m<sup>3</sup>;

Italy MDLPS

TWA: 5 ppm;

TWA: 8 mg/m<sup>3</sup>;

STEL: 10 ppm;

STEL: 15 mg/m<sup>3</sup>;

Ceiling Limit Value

2 ppm

3.0 mg/m<sup>3</sup>

Latvia

TWA: 5 ppm;

TWA: 8 mg/m<sup>3</sup>;

STEL: 10 ppm;

STEL: 15 mg/m<sup>3</sup>;

Netherlands

TWA: 5 ppm;

TWA: 8 mg/m<sup>3</sup>;

# SAFETY DATA SHEET

Product Name Buprenorphine Hydrochloride Injection (Hospira Inc.)  
Revision date 15-Jun-2025

Page 6 / 13  
Version 3

Poland	STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ; TWA-NDS: 5 mg/m <sup>3</sup> ; STEL-NDSch: 10 mg/m <sup>3</sup> ;
Romania	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Russia	MAC: 5 mg/m <sup>3</sup>
Slovakia	TWA: 5 ppm; TWA: 8.0 mg/m <sup>3</sup> ; Ceiling: 15 mg/m <sup>3</sup> ;
Spain	TWA-(VLA-ED): 5 ppm; TWA-(VLA-ED): 7.6 mg/m <sup>3</sup> ; STEL (VLA-EC): 10 ppm; STEL (VLA-EC): 15 mg/m <sup>3</sup> ;
Switzerland	TWA-MAK: 2 ppm; TWA-MAK: 3 mg/m <sup>3</sup> ; STEL-KZGW: 4 ppm; STEL-KZGW: 6 mg/m <sup>3</sup> ;
U.S. - OSHA - Final PELs - Ceiling Limits	5 ppm
OSHA PEL	7 mg/m <sup>3</sup> Ceiling: 5 ppm Ceiling: 7 mg/m <sup>3</sup> (vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m <sup>3</sup>
United Kingdom	TWA: 1 ppm; gas and aerosol mist TWA: 2 mg/m <sup>3</sup> ; gas and aerosol mist STEL: 5 ppm; gas and aerosol mist STEL: 8 mg/m <sup>3</sup> ; gas and aerosol mist

## 8.2. Exposure controls

### Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. It is recommended that all operations be fully enclosed and no air recirculated.

### Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

### Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

### Hand protection

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

### Skin and body protection

Impervious disposable protective clothing is recommended if skin contact with drug product

# SAFETY DATA SHEET

Product Name Buprenorphine Hydrochloride Injection (Hospira Inc.)  
Revision date 15-Jun-2025

Page 7 / 13  
Version 3

is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

## Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).

## Thermal hazards

No information available.

## Environmental exposure controls

No information available.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

Physical state	Liquid
Color	Colorless
Odor	No information available.
Odor threshold	No information available
<b>Property</b>	<b>Values</b>
Melting point / freezing point	No data available
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	3.5-5.5
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	No data available Soluble
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

### 9.2. Other information

Molecular formula	Mixture
Molecular weight	Mixture

#### 9.2.1. Information with regard to physical hazard classes

No information available

#### 9.2.2. Other safety characteristics

No information available

# SAFETY DATA SHEET

Product Name Buprenorphine Hydrochloride Injection (Hospira Inc.)  
Revision date 15-Jun-2025

Page 8 / 13  
Version 3

## Section 10: STABILITY AND REACTIVITY

### 10.1. Reactivity

Reactivity No information available.

### 10.2. Chemical stability

Stability Stable under normal conditions.

### Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

### 10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

### 10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

### 10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

### 10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

## Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

**General Information:** The information included in this section describes the potential hazards of the individual ingredients

**Short term** May cause central nervous system effects.

**Known Clinical Effects:** The most common adverse effects seen during clinical use of this drug include drowsiness, nausea, vomiting, decrease in blood pressure (hypotension), increase in blood pressure (hypertension), respiratory depression, decreased heart rate (bradycardia), increased heart rate (tachycardia), dizziness, sweating, headache, dry mouth, hallucinations.

**Acute toxicity** Based on available data, the classification criteria are not met.

**Serious eye damage/eye irritation** Based on available data, the classification criteria are not met.

**Skin corrosion/irritation** Based on available data, the classification criteria are not met.

**Respiratory or skin sensitization** Based on available data, the classification criteria are not met.

**STOT - single exposure** Based on available data, the classification criteria are not met.

**STOT - repeated exposure** Based on available data, the classification criteria are not met.

**Reproductive toxicity** Based on available data, the classification criteria are not met.

**Germ cell mutagenicity** Based on available data, the classification criteria are not met.

**Carcinogenicity** Based on available data, the classification criteria are not met.

**Aspiration hazard** Based on available data, the classification criteria are not met.

### Acute Toxicity: (Species, Route, End Point, Dose)

#### Buprenorphine Hydrochloride

Rat Oral LD50 > 1000 mg/kg

Mouse Oral LD50 800 mg/kg

Rat IV LD50 31-62 mg/kg

Mouse IV LD50 24-72 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg ( Rat )	-	-
+ Hydrochloric Acid	238 - 277 mg/kg ( Rat )	> 5010 mg/kg ( Rabbit )	= 1.68 mg/L ( Rat ) 1 h



# SAFETY DATA SHEET

Product Name Buprenorphine Hydrochloride Injection (Hospira Inc.)  
Revision date 15-Jun-2025

Page 9 / 13  
Version 3

Buprenorphine Hydrochloride	> 1 g/kg ( Rat )	-	-
-----------------------------	------------------	---	---

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

## **Irritation / Sensitization: (Study Type, Species, Severity)**

### **+ Hydrochloric Acid**

Skin irritation Severe

Eye irritation Severe

### **Buprenorphine Hydrochloride**

Guinea Pig Negative

Skin Irritation Rabbit Slight

## **Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

### **Buprenorphine Hydrochloride**

6 Month(s) Mini Pig Dermal 0.8 mg/kg/day NOAEL None identified

6 Month(s) Rabbit Dermal 15 mg/kg/day NOAEL None identified

6 Month(s) Dog Dermal 1 mg/kg/day NOAEL None identified

## **Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

### **Buprenorphine Hydrochloride**

Reproductive & Fertility Rat Oral 80 mg/kg/day NOAEL Negative, Fertility

Embryo / Fetal Development Rat Intramuscular Subcutaneous 5 mg/kg/day NOAEL Not Teratogenic

Embryo / Fetal Development Rabbit Intramuscular Subcutaneous 5 mg/kg/day NOAEL Not Teratogenic

Embryo / Fetal Development Rat Oral 160 mg/kg/day NOAEL Not Teratogenic

## **Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

### **+ Hydrochloric Acid**

Bacterial Mutagenicity (Ames) *Salmonella* Negative

*In Vivo* Micronucleus Rat Negative

### **Buprenorphine Hydrochloride**

Bacterial Mutagenicity (Ames) Equivocal

Mammalian Cell Mutagenicity Hamster liver Negative

Mammalian Cell Mutagenicity Mouse Lymphoma Negative

## **Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

### **Buprenorphine Hydrochloride**

27 Month(s) Rat Oral, in feed 56 mg/kg/day NOAEL Not carcinogenic

86 Week(s) Mouse Oral, in feed 100 mg/kg/day NOAEL Not carcinogenic

100 Week(s) Rat Dermal 20 mg/kg/day NOAEL Not carcinogenic

**Carcinogenicity** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

### **+ Hydrochloric Acid**

IARC

Group 3

## **11.2. Information on other hazards**

### **11.2.1. Endocrine disrupting properties**

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### **11.2.2. Other information**

**Other adverse effects** No information available.

# SAFETY DATA SHEET

Product Name Buprenorphine Hydrochloride Injection (Hospira Inc.)  
Revision date 15-Jun-2025

Page 10 / 13  
Version 3

## Section 12: ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided.

### 12.1. Toxicity

### 12.2. Persistence and degradability

**Persistence and degradability** No information available.

### 12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

### 12.4. Mobility in soil

**Mobility in soil** No information available.

### 12.5. Results of PBT and vPvB assessment

**PBT and vPvB assessment** Based on available data, the classification criteria are not met.

Chemical name	PBT and vPvB assessment
+ Hydrochloric Acid	Not PBT/vPvB PBT assessment does not apply

### 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### 12.7. Other adverse effects

**Other adverse effects** No information available.

**PMT or vPvM properties** Based on available data, the classification criteria are not met.

## Section 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

#### **Waste from residues/unused products**

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

# SAFETY DATA SHEET

Product Name Buprenorphine Hydrochloride Injection (Hospira Inc.)  
Revision date 15-Jun-2025

Page 11 / 13  
Version 3

**Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.**

UN number: Not applicable  
UN proper shipping name: Not applicable  
Transport hazard class(es): Not applicable  
Packing group: Not applicable  
Environmental Hazard(s): Not applicable

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

#### Dextrose

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present

#### + Hydrochloric Acid

CERCLA/SARA Section 313 de minimus %	1.0 %
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-595-7
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

#### Buprenorphine Hydrochloride

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
U.S. - DEA (Drug Enforcement Administration)	Schedule III Controlled Substance
EINECS	258-396-8
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 8

### National regulations

#### Germany

Chemical Prohibition Ordinance (ChemVerbotsV)  
Not applicable

TRGS 905 Not applicable

#### Switzerland

# SAFETY DATA SHEET

Product Name Buprenorphine Hydrochloride Injection (Hospira Inc.)  
Revision date 15-Jun-2025

Page 12 / 13  
Version 3

**Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018** Not applicable  
**Storage of Hazardous Material** Not applicable  
**WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20** Not applicable  
**Major Accidents Ordinance SR 814.012** Not applicable

## European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

### Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
+ Hydrochloric Acid 7647-01-0	75	-

## Persistent Organic Pollutants

Not applicable

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid 7647-01-0	25	250

## Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
+ Hydrochloric Acid 7647-01-0	Product-type 2: Disinfectants and algacides not intended for direct application to humans or animals

## Explosives Precursors Marketing and Use (2019/1148)

Not applicable

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory  
**DSL/NDL** - Canadian Domestic Substances List/Non-Domestic Substances List  
**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances  
**ENCS** - Japan Existing and New Chemical Substances  
**IECSC** - China Inventory of Existing Chemical Substances  
**KECL** - Korean Existing Chemicals Inventory  
**PICCS** - Philippines Inventory of Chemicals and Chemical Substances  
**AICS** - Australian Inventory of Chemical Substances  
**NZIoC** - New Zealand Inventory of Chemicals  
**TCSI** - Taiwan Chemical Substance Inventory

## 15.2. Chemical safety assessment

**Chemical Safety Report** No information available

## Section 16: OTHER INFORMATION

**Key or legend to abbreviations and acronyms used in the safety data sheet**

# SAFETY DATA SHEET

Product Name Buprenorphine Hydrochloride Injection (Hospira Inc.)  
Revision date 15-Jun-2025

Page 13 / 13  
Version 3

---

## Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H302 - Harmful if swallowed H314 - Causes severe skin burns and eye damage H336 - May cause drowsiness or dizziness H331 - Toxic if inhaled

**Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information.

**Reason for revision** Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 16 - Other Information.

**Revision date** 15-Jun-2025

**Prepared By** Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**